Abstract
Background The current standard for coronavirus 2019 disease (COVID-19) diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR) testing of naso-pharyngeal swabs (NPS), Sampling with NPS is invasive and requires specialized and trained personnel, which limits rapid and repeated screening for the disease. A less invasive and possibly self-administered sampling method may increase the capacity for testing and be more effective in identifying, isolating, and filtering out currently infected persons.
Methods Over a period of three months, we included volunteers presenting with recent symptoms suggestive of a SARS-CoV-2 infection at a free COVID-19 screening center in the city of Nice, France. NPS as well as nasal and oral sponges were collected in parallel and analyzed by RT-PCR for SARS-CoV-2.
Results One hundred and forty-seven subjects were included, of whom, 41.5% were diagnosed with COVID-19 using NPS RT-PCR. RT-PCR on nasal and oral sponges showed a sensitivity of 87 to 98% and 72 to 87%, respectively for diagnosis of COVID-19 in symptomatic subjects, depending on the type of RT-PCR technique used. The specificity was 100% whatever the RT-PCR test. The viral load determined with the oral samples was significantly lower than with NPS.
Conclusion Taken together, these results demonstrated that the oral sponge sampling method can be standardized, is easy to use and cheap. The acceptability makes it a repeatable test, notably for elderly people or children. It may become a high-frequency - low analytical sensitive testing strategy.
Summary of the “take home” message Oral sponge sampling for SARS-CoV2 RT-PCR, is easy to use, can be self-administered with a sensitivity of up to 87 % in symptomatic patients.
Competing Interest Statement
Paul Hofman is a member of the scientific advisory board (group of european experts) of Biocartis. However, this boad is totally independ of Biocartis
Clinical Trial
NCT04418206
Funding Statement
This work was supported by Conseil Departemental 06, Ville de Nice, Metropole Nice Cote d'Azur, Fonds de Dotation AVENI, and from private donators. Acknowledgements: Special thanks to E. Faidhi, N. Fridlyand, A. Rauscher, E. Maris, the Lauro family and to the many private donators for their generous contribution.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The promoter of the study was the Center Hospitalier Universitaire de Nice. The agreement for the study of the Institutional review board Sud Mediterranee V was obtained on April 22, 2020 (registration # 20.04014.35208). SHAM liability insurance (n 159087).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data referred to in this manuscript can be available after contacting the corresponding author
